BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35017325)

  • 1. Could Omega 3 fatty acids reduce the risk of contrast-induced nephropathy in patients undergoing coronary angiography? A randomized controlled trial.
    Alrowaie FA; Almatham KI; Alsamadi F; Bashir MS; Munshi HH
    Saudi J Kidney Dis Transpl; 2021; 32(2):328-335. PubMed ID: 35017325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial.
    Habib M; Hillis A; Hammad A
    Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):55-61. PubMed ID: 26787567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial.
    Amini M; Salarifar M; Amirbaigloo A; Masoudkabir F; Esfahani F
    Trials; 2009 Jun; 10():45. PubMed ID: 19563648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial.
    Koc F; Ozdemir K; Kaya MG; Dogdu O; Vatankulu MA; Ayhan S; Erkorkmaz U; Sonmez O; Aygul MU; Kalay N; Kayrak M; Karabag T; Alihanoglu Y; Gunebakmaz O
    Int J Cardiol; 2012 Mar; 155(3):418-23. PubMed ID: 21106264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is treatment with N-acetylcysteine to prevent contrast-induced nephropathy when using bicarbonate hydration out of date?
    Heng AE; Cellarier E; Aublet-Cuvelier B; Decalf V; Motreff P; Marcaggi X; Deteix P; Souweine B
    Clin Nephrol; 2008 Dec; 70(6):475-84. PubMed ID: 19049703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of acute renal failure post-contrast imaging in cardiology: a randomized study.
    Alessandri N; Lanzi L; Garante CM; Tersigni F; Sergiacomi R; Petrassi M; Di Matteo A; Tufano F
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17 Suppl 1():13-21. PubMed ID: 23436661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use and efficacy of saline hydration and N-acetyl cysteine to prevent contrast-induced nephropathy in low-risk populations undergoing coronary artery angiography.
    CalabrĂ² P; Bianchi R; Crisci M; Caprile M; Bigazzi MC; Palmieri R; Golia E; De Vita A; Romano IJ; Limongelli G; Russo MG; CalabrĂ² R
    Intern Emerg Med; 2011 Dec; 6(6):503-7. PubMed ID: 21279477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
    Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE
    Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
    Jo SH; Koo BK; Park JS; Kang HJ; Kim YJ; Kim HL; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS
    Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Contrast nephropathy in cardiac procedures: no advantages with prophylactic use of N-acetylcysteine (NAC)].
    Vallero A; Cesano G; Pozzato M; Garbo R; Minelli M; Quarello F; Formica M
    G Ital Nefrol; 2002; 19(5):529-33. PubMed ID: 12439841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature.
    Goldenberg I; Shechter M; Matetzky S; Jonas M; Adam M; Pres H; Elian D; Agranat O; Schwammenthal E; Guetta V
    Eur Heart J; 2004 Feb; 25(3):212-8. PubMed ID: 14972421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of N-acetylcysteine on cystatin C-based renal function after elective coronary angiography (ENABLE Study): a prospective, randomized trial.
    Kim BJ; Sung KC; Kim BS; Kang JH; Lee KB; Kim H; Lee MH
    Int J Cardiol; 2010 Feb; 138(3):239-45. PubMed ID: 18793808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of hydration with or without n-acetylcysteine on contrast induced nephropathy in patients undergoing coronary angiography and percutaneous coronary intervention.
    Awal A; Ahsan SA; Siddique MA; Banerjee S; Hasan MI; Zaman SM; Arzu J; Subedi B
    Mymensingh Med J; 2011 Apr; 20(2):264-9. PubMed ID: 21522098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prehydration alone is sufficient to prevent contrast-induced nephropathy after day-only angiography procedures--a randomised controlled trial.
    Kotlyar E; Keogh AM; Thavapalachandran S; Allada CS; Sharp J; Dias L; Muller D
    Heart Lung Circ; 2005 Dec; 14(4):245-51. PubMed ID: 16360994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity.
    Briguori C; Colombo A; Airoldi F; Violante A; Castelli A; Balestrieri P; Paolo Elia P; Golia B; Lepore S; Riviezzo G; Scarpato P; Librera M; Focaccio A; Ricciardelli B
    J Am Coll Cardiol; 2004 Aug; 44(4):762-5. PubMed ID: 15312855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial comparing hydration therapy to additional hemodialysis or N-acetylcysteine for the prevention of contrast medium-induced nephropathy: the Dialysis-versus-Diuresis (DVD) Trial.
    Reinecke H; Fobker M; Wellmann J; Becke B; Fleiter J; Heitmeyer C; Breithardt G; Hense HW; Schaefer RM
    Clin Res Cardiol; 2007 Mar; 96(3):130-9. PubMed ID: 17180572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast.
    Boccalandro F; Amhad M; Smalling RW; Sdringola S
    Catheter Cardiovasc Interv; 2003 Mar; 58(3):336-41. PubMed ID: 12594698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of intravenous n-acetylcysteine to prevent contrast induced nephropathy in acute coronary syndromes.
    Jaffery Z; Verma A; White CJ; Grant AG; Collins TJ; Grise MA; Jenkins JS; McMullan PW; Patel RA; Reilly JP; Thornton SN; Ramee SR
    Catheter Cardiovasc Interv; 2012 May; 79(6):921-6. PubMed ID: 21542122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography.
    Durham JD; Caputo C; Dokko J; Zaharakis T; Pahlavan M; Keltz J; Dutka P; Marzo K; Maesaka JK; Fishbane S
    Kidney Int; 2002 Dec; 62(6):2202-7. PubMed ID: 12427146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does N-acetylcysteine reduce the incidence of contrast-induced nephropathy and clinical events in patients undergoing primary angioplasty for acute myocardial infarction?
    Tanaka A; Suzuki Y; Suzuki N; Hirai T; Yasuda N; Miki K; Fujita M; Tanaka T
    Intern Med; 2011; 50(7):673-7. PubMed ID: 21467697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.